These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. SCIB1, a huIgG1 antibody DNA vaccination, combined with PD-1 blockade induced efficient therapy of poorly immunogenic tumors. Xue W; Brentville VA; Symonds P; Cook KW; Yagita H; Metheringham RL; Durrant LG Oncotarget; 2016 Dec; 7(50):83088-83100. PubMed ID: 27825115 [TBL] [Abstract][Full Text] [Related]
5. The present status and future prospects of peptide-based cancer vaccines. Hirayama M; Nishimura Y Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694 [TBL] [Abstract][Full Text] [Related]
6. Exploiting Preexisting Immunity to Enhance Oncolytic Cancer Immunotherapy. Tähtinen S; Feola S; Capasso C; Laustio N; Groeneveldt C; Ylösmäki EO; Ylösmäki L; Martins B; Fusciello M; Medeot M; Tagliamonte M; Chiaro J; Hamdan F; Peltonen K; Ranki T; Buonaguro L; Cerullo V Cancer Res; 2020 Jun; 80(12):2575-2585. PubMed ID: 32107211 [TBL] [Abstract][Full Text] [Related]
7. Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. Duperret EK; Wise MC; Trautz A; Villarreal DO; Ferraro B; Walters J; Yan J; Khan A; Masteller E; Humeau L; Weiner DB Mol Ther; 2018 Feb; 26(2):435-445. PubMed ID: 29249395 [TBL] [Abstract][Full Text] [Related]
8. Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy. Lee KL; Benz SC; Hicks KC; Nguyen A; Gameiro SR; Palena C; Sanborn JZ; Su Z; Ordentlich P; Rohlin L; Lee JH; Rabizadeh S; Soon-Shiong P; Niazi K; Schlom J; Hamilton DH Cancer Immunol Res; 2019 Aug; 7(8):1359-1370. PubMed ID: 31292145 [TBL] [Abstract][Full Text] [Related]
9. A New Strategy Toward B Cell-Based Cancer Vaccines by Active Immunization With Mimotopes of Immune Checkpoint Inhibitors. Tobias J; Battin C; De Sousa Linhares A; Lebens M; Baier K; Ambroz K; Drinić M; Högler S; Inic-Kanada A; Garner-Spitzer E; Preusser M; Kenner L; Kundi M; Zielinski CC; Steinberger P; Wiedermann U Front Immunol; 2020; 11():895. PubMed ID: 32528470 [TBL] [Abstract][Full Text] [Related]
10. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity. Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075 [TBL] [Abstract][Full Text] [Related]
11. Anti-pancreatic tumor efficacy of a Listeria-based, Annexin A2-targeting immunotherapy in combination with anti-PD-1 antibodies. Kim VM; Blair AB; Lauer P; Foley K; Che X; Soares K; Xia T; Muth ST; Kleponis J; Armstrong TD; Wolfgang CL; Jaffee EM; Brockstedt D; Zheng L J Immunother Cancer; 2019 May; 7(1):132. PubMed ID: 31113479 [TBL] [Abstract][Full Text] [Related]
12. Stimulation of Oncogene-Specific Tumor-Infiltrating T Cells through Combined Vaccine and αPD-1 Enable Sustained Antitumor Responses against Established HER2 Breast Cancer. Crosby EJ; Acharya CR; Haddad AF; Rabiola CA; Lei G; Wei JP; Yang XY; Wang T; Liu CX; Wagner KU; Muller WJ; Chodosh LA; Broadwater G; Hyslop T; Shepherd JH; Hollern DP; He X; Perou CM; Chai S; Ashby BK; Vincent BG; Snyder JC; Force J; Morse MA; Lyerly HK; Hartman ZC Clin Cancer Res; 2020 Sep; 26(17):4670-4681. PubMed ID: 32732224 [TBL] [Abstract][Full Text] [Related]
13. Targeting Neoepitopes to Treat Solid Malignancies: Immunosurgery. de Sousa E; Lérias JR; Beltran A; Paraschoudi G; Condeço C; Kamiki J; António PA; Figueiredo N; Carvalho C; Castillo-Martin M; Wang Z; Ligeiro D; Rao M; Maeurer M Front Immunol; 2021; 12():592031. PubMed ID: 34335558 [TBL] [Abstract][Full Text] [Related]
14. Combination of Photodynamic Therapy and Specific Immunotherapy Efficiently Eradicates Established Tumors. Kleinovink JW; van Driel PB; Snoeks TJ; Prokopi N; Fransen MF; Cruz LJ; Mezzanotte L; Chan A; Löwik CW; Ossendorp F Clin Cancer Res; 2016 Mar; 22(6):1459-68. PubMed ID: 26546617 [TBL] [Abstract][Full Text] [Related]
15. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
16. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40. Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348 [No Abstract] [Full Text] [Related]
17. TNFR2 blockade alone or in combination with PD-1 blockade shows therapeutic efficacy in murine cancer models. Case K; Tran L; Yang M; Zheng H; Kuhtreiber WM; Faustman DL J Leukoc Biol; 2020 Jun; 107(6):981-991. PubMed ID: 32449229 [TBL] [Abstract][Full Text] [Related]
18. Next generation approaches for tumor vaccination. Patel A; Kaufman HL; Disis ML Chin Clin Oncol; 2017 Apr; 6(2):19. PubMed ID: 28482672 [TBL] [Abstract][Full Text] [Related]
19. Therapeutic Cancer Vaccine and Combinations With Antiangiogenic Therapies and Immune Checkpoint Blockade. Mougel A; Terme M; Tanchot C Front Immunol; 2019; 10():467. PubMed ID: 30923527 [TBL] [Abstract][Full Text] [Related]